HLA-C and neoplasm: Next generation precision immunotherapy clinical trials should ascertain the immune environment of each tumor and host, including but not limited to mutational burden, neo-antigen immunogenicity, ability of MHC to present neo-antigens as well as T cells to recognize them, and checkpoints exploited by the tumor.